Emerging Company Profile

Article


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1fh3me1dm0">Arch-backed Neumora: using data tools for precision neuroscience</h1><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1fh3me7lj0">
    <span class="ng-tns-c17-4" doc-editable="text">By Paul Bonanos, Associate Editor</span>
</div><div class="date" data-component-id="doc-1fh3mec8j0">
  <span class="byline" doc-editable="text"></span>
</div><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1fh3men3r0">Deep-pocketed Arch, partner Amgen back Neumora&#x2019;s eight-program pipeline in neuroscience</h2></div></div></div>


Arch Venture Partners

Neumora Therapeutics Inc.

Kappa opioid receptor (KOR) (OPRK1)

Vasopressin 1a (V1a) receptor

Serotonin receptor 2A (5-HT2A) (HT2RA)

NMDA receptor NR2A subtype (GRIN2A) (NR2A)

NMDA receptor NR2B subtype (GRIN2B) (NR2B) (GluN2B)

Casein kinase 1 (CSNK1) (CKI)

Glucosylceramidase beta (GBA; GCase)

Arch-backed Neumora: using data tools for precision neuroscience

Deep-pocketed Arch, partner Amgen back Neumora’s eight-program pipeline in neuroscience

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>